Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763715 | 1.00 | MAPK14 (0.40) | MAPK14MAPK11BRD4ALDH1A1PTGS1 | |
| SCHEMBL13763716 | 1.00 | MAPK14 (0.40) | MAPK14MAPK11BRD4ALDH1A1PTGS1 | |
| SCHEMBL3971775 | 0.87 | MAPK14 (0.41) | MAPK14MAPK11BRD4PTGS1PTGS2 | |
| SCHEMBL13763718 | 0.87 | MAPK14 (0.41) | MAPK14MAPK11BRD4PTGS1PTGS2 | |
| SCHEMBL4016140 | 0.86 | MAPK14 (0.38) | MAPK14MAPK11 | |
| SCHEMBL4016129 | 0.86 | MAPK14 (0.38) | MAPK14MAPK11 | |
| SCHEMBL3968994 | 0.84 | MAPK14 (0.43) | MAPK14MAPK11BRD4PTGS1PTGS2 | |
| SCHEMBL4844719 | 0.84 | MAPK14 (0.42) | MAPK14MAPK11 | |
| SCHEMBL14019063 | 0.84 | MAPK14 (0.42) | MAPK14MAPK11 | |
| SCHEMBL13763717 | 0.84 | MAPK14 (0.43) | MAPK14MAPK11BRD4PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | claimed |
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | MAPK1, MAPK3, MAP3K1 | MAPK14 36/4885MAPK11 31/4885BRD4 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.